Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CHR563
MIFTS: 50

Chronic Eosinophilic Leukemia

Categories: Cancer diseases, Blood diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Chronic Eosinophilic Leukemia

About this section

MalaCards integrated aliases for Chronic Eosinophilic Leukemia:

Name: Chronic Eosinophilic Leukemia 59 37 73
Pdgfra-Associated Chronic Eosinophilic Leukemia 73

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34 33
Orphanet: 59  
Rare haematological diseases


External Ids:

Orphanet 59 ORPHA168940
UMLS via Orphanet 74 C0346421
ICD10 via Orphanet 34 D47.5
KEGG 37 H01590
ICD10 33 D47.5
Sources

Summaries for Chronic Eosinophilic Leukemia

About this section
MalaCards based summary : Chronic Eosinophilic Leukemia, also known as pdgfra-associated chronic eosinophilic leukemia, is related to pdgfra-associated chronic eosinophilic leukemia and loeffler endocarditis. An important gene associated with Chronic Eosinophilic Leukemia is FIP1L1 (Factor Interacting With PAPOLA And CPSF1), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 76 Chronic eosinophilic leukemia (CEL) is a disease in which too many eosinophils (a type of white blood... more...

Sources

Related Diseases for Chronic Eosinophilic Leukemia

About this section

Diseases related to Chronic Eosinophilic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Related Disease Score Top Affiliating Genes
1 pdgfra-associated chronic eosinophilic leukemia 34.9 FIP1L1 PDGFRA
2 loeffler endocarditis 30.6 FIP1L1 PDGFRA
3 endomyocardial fibrosis 30.6 FIP1L1 PDGFRA
4 myeloproliferative neoplasm 30.2 ABL1 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
5 mast cell disease 30.0 KIT PDGFRA PDGFRB
6 leukemia 29.9 ABL1 FLT3 KIT WT1
7 systemic mastocytosis 29.4 FGFR1 FIP1L1 KIT PDGFRA PDGFRB
8 acute leukemia 29.3 FLT3 KIT WT1
9 hypereosinophilic syndrome, idiopathic 29.1 FIP1L1 KIT PDGFRA PDGFRB WT1
10 myeloid leukemia 28.8 ABL1 FLT3 KIT WT1
11 leukemia, acute myeloid 28.5 ABL1 FLT3 KIT WT1
12 myelofibrosis 28.5 FLT3 IFNA1 KIT
13 hypereosinophilic syndrome 27.7 ABL1 FGFR1 FIP1L1 IFNA1 KIT PDGFRA
14 pdgfrb-associated chronic eosinophilic leukemia 12.4
15 reticular perineurioma 10.7 KIT PDGFRA
16 gastric leiomyosarcoma 10.6 KIT PDGFRA
17 sarcomatoid renal cell carcinoma 10.6 KIT PDGFRA
18 conventional fibrosarcoma 10.6 KIT PDGFRA
19 endometrial small cell carcinoma 10.6 KIT PDGFRA
20 pulmonary vein stenosis 10.6 KIT PDGFRA
21 acute myeloblastic leukemia with maturation 10.6 FLT3 KIT
22 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.6 FLT3 KIT
23 undifferentiated pleomorphic sarcoma 10.5 KIT PDGFRA
24 lung adenoid cystic carcinoma 10.5 KIT PDGFRA
25 cellular neurofibroma 10.4 ABL1 PDGFRB
26 sm-ahnmd 10.4 FIP1L1 KIT PDGFRA
27 carney triad 10.4 KIT PDGFRA
28 testicular gonadoblastoma 10.4 KIT WT1
29 corneal dystrophy, subepithelial mucinous 10.4 FIP1L1 PDGFRA PDGFRB
30 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.4 FLT3 KIT
31 mesenchymal cell neoplasm 10.4 KIT PDGFRA TPM3
32 neurofibromatosis, type i 10.4 KIT PDGFRA
33 desmoid tumor 10.3 KIT PDGFRA PDGFRB
34 fibrosarcoma of bone 10.3 KIT PDGFRA PDGFRB
35 dermatofibrosarcoma protuberans 10.3 KIT PDGFRA PDGFRB
36 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.3 FGFR1 PDGFRA PDGFRB
37 lymphoblastic leukemia, acute, with lymphomatous features 10.3 ABL1 FGFR1
38 cystic nephroma 10.3 KIT WT1
39 cytogenetically normal acute myeloid leukemia 10.3 FLT3 WT1
40 spindle cell liposarcoma 10.2 KIT WT1
41 chronic myelomonocytic leukemia 10.2 FLT3 KIT PDGFRB
42 atypical chronic myeloid leukemia 10.1 ABL1 FGFR1 PDGFRA
43 congenital mesoblastic nephroma 10.1 KIT WT1
44 juvenile myelomonocytic leukemia 10.1 FLT3 PDGFRA PDGFRB
45 myeloid sarcoma 10.1 FLT3 KIT
46 leukemia, acute lymphoblastic 3 10.0 ABL1 FLT3 PDGFRA
47 uterine sarcoma 10.0 KIT PDGFRB WT1
48 dysgerminoma of ovary 10.0 KIT WT1
49 primary hypereosinophilic syndrome 10.0 FGFR1 FIP1L1 PDGFRA PDGFRB
50 core binding factor acute myeloid leukemia 10.0 FLT3 KIT WT1

Graphical network of the top 20 diseases related to Chronic Eosinophilic Leukemia:



Diseases related to Chronic Eosinophilic Leukemia
Sources

Symptoms & Phenotypes for Chronic Eosinophilic Leukemia

About this section

GenomeRNAi Phenotypes related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

26 (show top 50) (show all 57)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.69 IFNA1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-14 10.69 IFNA1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-144 10.69 TPM3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 10.69 FLT3 IFNA1 TPM3 WT1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.69 KIT
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 10.69 FLT3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.69 TPM3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 10.69 IFNA1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.69 KIT
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 10.69 FLT3
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-187 10.69 FLT3
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 10.69 TPM3
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-209 10.69 IFNA1 TPM3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.69 TPM3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.69 TPM3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.69 IFNA1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-61 10.69 IFNA1 TPM3 KIT
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 10.69 TPM3
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 10.69 TPM3
20 Decreased viability GR00173-A 10.39 FLT3 PDGFRA
21 Decreased viability GR00221-A-1 10.39 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
22 Decreased viability GR00221-A-2 10.39 ABL1 FGFR1
23 Decreased viability GR00221-A-3 10.39 ABL1 PDGFRA PDGFRB
24 Decreased viability GR00221-A-4 10.39 FLT3 PDGFRA PDGFRB
25 Decreased viability GR00301-A 10.39 KIT
26 Decreased viability GR00342-S-1 10.39 PDGFRB ABL1
27 Decreased viability GR00342-S-2 10.39 ABL1
28 Decreased viability GR00342-S-3 10.39 ABL1
29 Decreased viability GR00402-S-2 10.39 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
30 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.13 ABL1 WT1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.13 KIT
32 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.13 ABL1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.13 WT1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.13 ABL1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.13 ABL1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.13 KIT WT1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.13 ABL1 KIT
38 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.13 KIT
39 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.13 WT1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.13 WT1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.13 ABL1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.13 ABL1 KIT WT1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.13 WT1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.13 KIT
45 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.13 ABL1 WT1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.13 ABL1 WT1
47 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.13 ABL1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.13 ABL1 KIT WT1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.13 KIT
50 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.13 KIT

MGI Mouse Phenotypes related to Chronic Eosinophilic Leukemia:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.13 ABL1 CDK5RAP2 FGFR1 FLT3 KIT PDGFRA
2 hematopoietic system MP:0005397 10.11 ABL1 CDK5RAP2 FGFR1 FLT3 KIT OSM
3 immune system MP:0005387 10.03 ABL1 CDK5RAP2 FGFR1 FLT3 KIT PDGFRA
4 endocrine/exocrine gland MP:0005379 10.02 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
5 mortality/aging MP:0010768 10.02 ABL1 CDK5RAP2 FGFR1 FLT3 KIT PDGFRA
6 craniofacial MP:0005382 9.99 ABL1 CDK5RAP2 FGFR1 KIT PDGFRA PDGFRB
7 embryo MP:0005380 9.97 ABL1 FGFR1 KIT PDGFRA PDGFRB WT1
8 integument MP:0010771 9.88 CDK5RAP2 FGFR1 KIT OSM PDGFRA PDGFRB
9 muscle MP:0005369 9.87 FGFR1 KIT PDGFRA PDGFRB TPM3 WT1
10 nervous system MP:0003631 9.76 ABL1 CDK5RAP2 FGFR1 KIT OSM PDGFRA
11 neoplasm MP:0002006 9.65 CDK5RAP2 FLT3 KIT PDGFRA WT1
12 no phenotypic analysis MP:0003012 9.43 FGFR1 FLT3 KIT PDGFRA TPM3 WT1
13 skeleton MP:0005390 9.17 CDK5RAP2 FGFR1 FLT3 KIT PDGFRA PDGFRB
Sources

Drugs & Therapeutics for Chronic Eosinophilic Leukemia

About this section

Drugs for Chronic Eosinophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 265)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 1 52-24-4 5453
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
6 Antilymphocyte Serum Phase 4,Phase 2,Phase 1,Not Applicable
7 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
11
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
12
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
13
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
14
Mycophenolic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
15
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 128794-94-5 5281078
16
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
17
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
18
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
19
Ephedrine Approved Phase 3 299-42-3 9294
20
Pseudoephedrine Approved Phase 3 90-82-4 7028
21
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 1 123318-82-1 119182
22
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
23
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
24
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-02-2 5743
25
Melphalan Approved Phase 2, Phase 3,Phase 1,Not Applicable 148-82-3 4053 460612
26
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
27
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
28
Acyclovir Approved Phase 3 59277-89-3 2022
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
31
Thioguanine Approved Phase 3 154-42-7 2723601
32
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
33
Aldesleukin Approved Phase 3,Phase 2 85898-30-2, 110942-02-4
34
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
35
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
36
Moxifloxacin Approved, Investigational Phase 3,Not Applicable 354812-41-2, 151096-09-2 152946
37 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Not Applicable 979-32-8
38
Norgestimate Approved, Investigational Phase 3,Not Applicable 35189-28-7 6540478
39
Estradiol Approved, Investigational, Vet_approved Phase 3,Not Applicable 50-28-2 5757
40
Ethinyl Estradiol Approved Phase 3,Not Applicable 57-63-6 5991
41
Polyestradiol phosphate Approved Phase 3,Not Applicable 28014-46-2
42
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
43
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
44 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
45 Staurosporine Experimental Phase 3 62996-74-1
46 Analgesics Phase 3,Phase 2,Phase 1,Not Applicable
47 Central Nervous System Depressants Phase 3,Phase 2,Phase 1,Not Applicable
48 Gemtuzumab Phase 2, Phase 3,Phase 3
49 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
50 Anesthetics Phase 3

Interventional clinical trials:

(show top 50) (show all 174)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Steroid Treatment for Hypereosinophilic Syndrome Recruiting NCT01524536 Phase 4 Corticosteroids
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
5 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
6 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
9 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
10 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
11 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
12 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
13 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
14 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
15 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
16 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
17 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
18 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
19 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
20 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
21 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
22 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
23 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
24 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
25 Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias Unknown status NCT00276926 Phase 2 STI571
26 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
27 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
28 Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes Completed NCT00787384 Phase 2 Imatinib
29 A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Blood Related Cancers Completed NCT00109707 Phase 1, Phase 2 Nilotinib
30 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
31 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
32 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
33 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
34 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2 busulfan;fludarabine phosphate
35 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant Completed NCT00691015 Phase 2 busulfan;carmustine;cyclophosphamide;cytarabine;etoposide;fludarabine phosphate;melphalan;anti-thymocyte globulin IV
36 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
37 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide
38 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
39 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
40 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
41 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
42 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
43 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
44 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
45 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
46 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
47 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
48 Combination Chemotherapy and Antithymocyte Globulin in Reducing Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplantation For Myelodysplastic Syndrome or Myeloproliferative Disorder Completed NCT00054340 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
49 Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder Completed NCT00049634 Phase 1, Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate
50 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate

Search NIH Clinical Center for Chronic Eosinophilic Leukemia

Sources

Genetic Tests for Chronic Eosinophilic Leukemia

About this section
Sources

Anatomical Context for Chronic Eosinophilic Leukemia

About this section

MalaCards organs/tissues related to Chronic Eosinophilic Leukemia:

41
Myeloid, Bone, Bone Marrow, Eye, Liver, T Cells, Testes
Sources

Publications for Chronic Eosinophilic Leukemia

About this section

Articles related to Chronic Eosinophilic Leukemia:

(show top 50) (show all 75)
# Title Authors Year
1
Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRI+ kinase inhibitor for PDGFRI+ driving chronic eosinophilic leukemia. ( 29544149 )
2018
2
A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34). ( 29384404 )
2018
3
A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. ( 29892549 )
2018
4
Integration of a bacterial gene sequence into a chronic eosinophilic leukemia patient's genome as part of a fusion gene linker. ( 28593047 )
2017
5
Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. ( 28495918 )
2017
6
Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib. ( 28651427 )
2017
7
Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in china. ( 27120808 )
2016
8
Complete remission of disseminated granulomatous dermatitis related to chronic eosinophilic leukemia following allogeneic stem cell transplantation. ( 27267816 )
2016
9
Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia. ( 27458550 )
2016
10
Chronic Eosinophilic Leukemia Presenting Predominantly with Cutaneous Manifestations. ( 27512192 )
2016
11
Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified. ( 27174585 )
2016
12
Chronic eosinophilic leukemia with FIP1L1-PDGFRA rearrangement. ( 27722133 )
2016
13
Chronic eosinophilic leukemia with a FIP1L1-PDGFRA rearrangement: Two case reports and a review of Korean cases. ( 25830134 )
2015
14
Delayed diagnosis leading to accelerated phase chronic eosinophilic leukemia due to a cytogenetically cryptic, imatinib-responsive TNIP1-PDFGRB fusion gene. ( 26503642 )
2015
15
Imatinib non-responsive chronic eosinophilic leukemia with ETV6-PDGFRA fusion gene. ( 24975316 )
2015
16
Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia. ( 26492057 )
2015
17
Generalized Eruptive Histiocytosis Associated With FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia. ( 25923837 )
2015
18
Murine models of eosinophilic leukemia: a model of FIP1L1-PDGFRI+ initiated chronic eosinophilic leukemia/systemic mastocytosis. ( 24986627 )
2014
19
Chronic eosinophilic leukemia with monosomy 8 in a five-year-old girl: a rare case. ( 25818969 )
2014
20
Chronic eosinophilic leukemia: a rare cause of hypereosinophilic syndrome. ( 25065049 )
2014
21
FIP1L1-PDGFRA-Positive Chronic Eosinophilic Leukemia: A Low-Burden Disease with Dramatic Response to Imatinib - A Report of 5 Cases from South India. ( 24764730 )
2014
22
Identification of kit(M541L) somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response. ( 25015329 )
2014
23
Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRI+: roles of Mcl-1 and I^-catenin. ( 24472312 )
2014
24
Successful treatment with imatinib in a patient with chronic eosinophilic leukemia not otherwise specified. ( 24449233 )
2014
25
Chronic eosinophilic leukemia with FIP1L1-PDGFRA. ( 23550302 )
2013
26
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study. ( 24057647 )
2013
27
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. ( 23630205 )
2013
28
Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia. ( 23621172 )
2013
29
The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. ( 23982058 )
2013
30
Chronic Eosinophilic Leukemia-Not Otherwise Specified (NOS) in the Background of a Large Cell Lymphoma. ( 24224106 )
2013
31
Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. ( 22449623 )
2012
32
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. ( 21818111 )
2012
33
Chronic eosinophilic leukemia presenting with mouth and penile ulcers. ( 22681908 )
2012
34
Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t(8;9)(p22;p24)/PCM1-JAK2-positive chronic eosinophilic leukemia. ( 22899477 )
2012
35
Successful treatment of ulcerative colitis associated with hypereosinophilic syndrome/chronic eosinophilic leukemia. ( 21841337 )
2011
36
Comparative proteomic analysis of blood eosinophils reveals redox signaling modifications in patients with FIP1L1-PDGFRA-associated chronic eosinophilic leukemia. ( 21302907 )
2011
37
Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion. ( 21072821 )
2011
38
Concomitant FIP1L1-PDGFRA fusion gene and T-cell clonality in a case of chronic eosinophilic leukemia with clonal evolution and an incomplete response to imatinib. ( 21281241 )
2011
39
Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. ( 20558942 )
2010
40
Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia. ( 20726440 )
2010
41
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. ( 19118067 )
2009
42
Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia. ( 19761433 )
2009
43
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. ( 19210352 )
2009
44
FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. ( 18539901 )
2008
45
Chronic eosinophilic leukemia/hypereosinophilic syndrome. ( 18283783 )
2008
46
PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. ( 17549478 )
2008
47
Elevated serum levels of soluble interleukin-2 receptor in chronic eosinophilic leukemia/hypereosinophilic syndrome with FIP1L1-PDGFR alpha fusion gene. ( 18365140 )
2008
48
FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib. ( 18706197 )
2008
49
Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy. ( 18028420 )
2008
50
A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint. ( 17591942 )
2007
Sources

Variations for Chronic Eosinophilic Leukemia

About this section
Sources

Expression for Chronic Eosinophilic Leukemia

About this section
Search GEO for disease gene expression data for Chronic Eosinophilic Leukemia.
Sources

Pathways for Chronic Eosinophilic Leukemia

About this section

Pathways related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.81 ABL1 FGFR1 FLT3 IFNA1 KIT OSM
2
PEDF Induced Signaling 64
Show member pathways
 13.47 FGFR1 FLT3 IFNA1 KIT OSM PDGFRA
3
TGF-Beta Pathway 64
Show member pathways
 13.31 FGFR1 FLT3 IFNA1 KIT PDGFRA PDGFRB
4
Akt Signaling 64
Show member pathways
 13.2 FGFR1 FLT3 KIT OSM PDGFRA PDGFRB
5
Cytokine Signaling in Immune system 66
Show member pathways
 13.11 FGFR1 FLT3 IFNA1 KIT OSM PDGFRA
6
PAK Pathway 64
Show member pathways
 13.09 FGFR1 KIT OSM PDGFRA PDGFRB
7
Nanog in Mammalian ESC Pluripotency 64
Show member pathways
 13.06 FGFR1 FLT3 KIT PDGFRA PDGFRB
8
Actin Nucleation by ARP-WASP Complex 64
Show member pathways
 12.75 FGFR1 FLT3 KIT PDGFRA PDGFRB
9
PI3K-Akt signaling pathway 37
Show member pathways
 12.69 FGFR1 FLT3 IFNA1 KIT OSM PDGFRA
10
MAPK signaling pathway 1 37
12.58 FGFR1 FLT3 KIT PDGFRA PDGFRB
11
Endometrial cancer 37
Show member pathways
 12.55 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
12
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.54 FGFR1 KIT PDGFRA PDGFRB
13
Ras signaling pathway 37
Show member pathways
 12.52 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
14
Regulation of IFNA signaling 66
Show member pathways
 12.44 IFNA1 OSM PDGFRA PDGFRB
15
Pathways in cancer 37
11.95 ABL1 FGFR1 FLT3 IFNA1 KIT PDGFRA
16
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 11.9 FGFR1 PDGFRA PDGFRB
17
Angiogenesis (CST) 4
11.68 FGFR1 PDGFRA PDGFRB
18
VEGF Pathway (Tocris) 72
Show member pathways
 11.65 FGFR1 FLT3 KIT PDGFRB
19
Tyrosine Kinases / Adaptors 4
11.6 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
20
Gefitinib Pathway, Pharmacokinetics 61
Show member pathways
 11.46 ABL1 KIT PDGFRA PDGFRB
21
Central carbon metabolism in cancer 37
11.37 FGFR1 FLT3 KIT PDGFRA PDGFRB
22
Alzheimers Disease Pathway 64
11.32 FGFR1 PDGFRA PDGFRB
23
Vemurafenib Pathway, Pharmacodynamics 61
11.28 FGFR1 PDGFRA PDGFRB
24
Cytoskeleton remodeling_Role of PDGFs in cell migration 22
10.97 PDGFRA PDGFRB
25
Osteoblast Signaling 1
10.71 PDGFRA PDGFRB
Sources

GO Terms for Chronic Eosinophilic Leukemia

About this section

Cellular components related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.02 FGFR1 FLT3 KIT PDGFRA PDGFRB
2 intrinsic component of plasma membrane GO:0031226 8.96 PDGFRA PDGFRB

Biological processes related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 40)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.99 FGFR1 FLT3 KIT OSM PDGFRA PDGFRB
2 cytokine-mediated signaling pathway GO:0019221 9.96 FLT3 IFNA1 KIT OSM
3 MAPK cascade GO:0000165 9.94 FGFR1 KIT PDGFRA PDGFRB
4 positive regulation of protein kinase B signaling GO:0051897 9.88 FGFR1 KIT PDGFRA PDGFRB
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.88 ABL1 FLT3 KIT PDGFRA PDGFRB
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
7 positive regulation of cell migration GO:0030335 9.86 KIT PDGFRA PDGFRB
8 negative regulation of signal transduction GO:0009968 9.85 FGFR1 FLT3 KIT PDGFRA PDGFRB
9 male gonad development GO:0008584 9.84 KIT PDGFRB WT1
10 phosphatidylinositol phosphorylation GO:0046854 9.84 FGFR1 KIT PDGFRA PDGFRB
11 cell chemotaxis GO:0060326 9.81 KIT PDGFRA PDGFRB
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 FLT3 KIT OSM
13 positive regulation of MAP kinase activity GO:0043406 9.8 FGFR1 FLT3 KIT PDGFRB
14 phosphatidylinositol-mediated signaling GO:0048015 9.77 FGFR1 PDGFRA PDGFRB
15 positive regulation of kinase activity GO:0033674 9.77 FGFR1 FLT3 KIT PDGFRA PDGFRB
16 platelet-derived growth factor receptor signaling pathway GO:0048008 9.74 ABL1 PDGFRA PDGFRB
17 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.73 FLT3 KIT PDGFRA PDGFRB
18 protein autophosphorylation GO:0046777 9.73 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
19 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.72 FGFR1 FLT3 KIT PDGFRA PDGFRB
20 B cell proliferation GO:0042100 9.68 ABL1 IFNA1
21 adrenal gland development GO:0030325 9.68 PDGFRA WT1
22 male genitalia development GO:0030539 9.67 PDGFRA WT1
23 regulation of actin cytoskeleton reorganization GO:2000249 9.67 ABL1 PDGFRA
24 cardiac myofibril assembly GO:0055003 9.67 PDGFRA PDGFRB
25 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.65 PDGFRA PDGFRB
26 metanephric mesenchyme development GO:0072075 9.65 PDGFRB WT1
27 retina vasculature development in camera-type eye GO:0061298 9.64 PDGFRA PDGFRB
28 peptidyl-tyrosine phosphorylation GO:0018108 9.63 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
29 myeloid progenitor cell differentiation GO:0002318 9.62 FLT3 KIT
30 metanephric S-shaped body morphogenesis GO:0072284 9.61 PDGFRB WT1
31 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.61 ABL1 PDGFRB
32 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.59 PDGFRA PDGFRB
33 metanephric glomerular capillary formation GO:0072277 9.58 PDGFRA PDGFRB
34 positive regulation of MAPK cascade GO:0043410 9.43 FGFR1 FLT3 KIT OSM PDGFRA PDGFRB
35 positive regulation of phospholipase C activity GO:0010863 8.92 FGFR1 KIT PDGFRA PDGFRB
36 multicellular organism development GO:0007275 10.13 FGFR1 FLT3 KIT OSM PDGFRA PDGFRB
37 cell differentiation GO:0030154 10.09 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
38 phosphorylation GO:0016310 10.03 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
39 protein phosphorylation GO:0006468 10.02 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
40 negative regulation of apoptotic process GO:0043066 10 FGFR1 FLT3 KIT PDGFRA PDGFRB WT1

Molecular functions related to Chronic Eosinophilic Leukemia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.93 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
2 transmembrane signaling receptor activity GO:0004888 9.88 FGFR1 FLT3 KIT PDGFRA PDGFRB
3 protein kinase activity GO:0004672 9.88 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
4 nucleotide binding GO:0000166 9.85 FGFR1 KIT PDGFRA PDGFRB
5 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.73 FGFR1 KIT PDGFRA PDGFRB
6 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.67 FGFR1 KIT PDGFRA PDGFRB
7 MAP kinase kinase kinase activity GO:0004709 9.65 FGFR1 FLT3 KIT PDGFRA PDGFRB
8 growth factor binding GO:0019838 9.62 FLT3 KIT PDGFRA PDGFRB
9 mitogen-activated protein kinase kinase binding GO:0031434 9.55 FGFR1 FLT3 KIT PDGFRA PDGFRB
10 platelet-derived growth factor receptor binding GO:0005161 9.54 PDGFRA PDGFRB
11 platelet-derived growth factor binding GO:0048407 9.52 PDGFRA PDGFRB
12 vascular endothelial growth factor-activated receptor activity GO:0005021 9.51 FLT3 PDGFRA
13 vascular endothelial growth factor binding GO:0038085 9.49 PDGFRA PDGFRB
14 protein tyrosine kinase activity GO:0004713 9.43 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
15 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.02 FGFR1 FLT3 KIT PDGFRA PDGFRB
16 transferase activity GO:0016740 10.04 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
17 ATP binding GO:0005524 10.03 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
Sources

Sources for Chronic Eosinophilic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....